SCHEMBL16474644

SCHEMBL16474644

Cc1cc(=O)n(-c2ccc(OC(F)(F)F)cc2)cc1-c1ccc2nccn2c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 6/20 0.42
SCN5A Q14524 4/20 0.41
PDE3A Q14432 2/20 0.41
PDE4A P27815 1/20 0.41
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP1A2 P05177 1/20 0.40
METAP2 P50579 1/20 0.40
PDE3B Q13370 1/20 0.40
MCHR1 Q99705 2/20 0.39
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
TGFBR1 P36897 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18077739 0.87 PDE3A (0.41) GRM2PDE3APDE4ACYP3A4HPGD
SCHEMBL16474641 0.85 KDM4E (0.40) CYP1A2MCHR1KDM4EGAAMAPT
SCHEMBL17151303 0.83 GRM2 (0.41) GRM2SCN5APDE3APDE4ACYP3A4
SCHEMBL16474635 0.81 POLB (0.41) SCN5AMCHR1KDM4EGAAMAPT
SCHEMBL16479449 0.80 MCHR1 (0.43) SCN5AMCHR1KDM4EGAAMAPT
SCHEMBL16474612 0.80 MCHR1 (0.43) SCN5AMCHR1KDM4EGAAMAPT
SCHEMBL17151307 0.79 SCN5A (0.40) GRM2SCN5APDE3APDE4ACYP3A4
SCHEMBL16474554 0.78 MCHR1 (0.41) MCHR1KDM4EGAAMAPTMAPK1
SCHEMBL16474633 0.78 PPARD (0.40) SCN5AMCHR1KDM4EGAAMAPT
SCHEMBL16475244 0.78 MAPT (0.43) CYP1A2MCHR1KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 GRM2 4047/4885SCN5A 3702/4885PDE3A 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.